07:00 , Sep 19, 2016 |  BioCentury  |  Emerging Company Profile

Solid CARs

Long-standing doubts about whether CAR T cells would be effective against solid tumors were exacerbated last year after Novartis AG and the University of Pennsylvania reported that their CART-meso showed no complete or partial responses...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Company News

Chimeric Therapeutics, Cancer Research UK, Cell Therapy Catapult, University of Birmingham cancer, gene/cell therapy news

Cancer Research UK’s Cancer Research Technology (CRT) Ltd. commercialization and development arm, the university and Cell Therapy Catapult partnered to launch newco Chimeric to develop a chimeric antigen receptor (CAR) T cell therapy targeting C-type...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Athersys, Cell Therapy Catapult deal

In January, Athersys and Cell Therapy Catapult partnered to evaluate Athersys’ MultiStem in a U.K. Phase IIa trial to treat acute respiratory distress syndrome (ARDS), which is expected to start next half. MultiStem, which is...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Cell Therapy Catapult, Plasticell, University of Oxford deal

Cell Therapy Catapult, Plasticell and the university partnered to develop a process to expand cord blood stem cells ex vivo. Cell Therapy Catapult will provide the consortium with cell therapy manufacturing services. Plasticell will use...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Azellon, Cell Therapy Catapult, NHS Blood and Transplant, University of Liverpool deal

Azellon, Cell Therapy, the university and NHSBT partnered to develop an allogeneic version of Azellon’s Cell Bandage meniscal tear stem cell therapy. NHSBT said its Advanced Therapy Unit will produce cell banks to prepare for...
07:00 , May 11, 2015 |  BC Week In Review  |  Company News

Sartorius, Cell Therapy Catapult deal

Sartorius’ TAP Biosystems subsidiary and Cell Therapy Catapult partnered to develop a small scale, single-use bioreactor for cell therapy. Development will be funded by an undisclosed grant from the U.K. government’s Innovate UK. The partners...
08:00 , Jan 12, 2015 |  BC Week In Review  |  Clinical News

WT1 TCR-transduced T cells: Phase I/II started

Cell Therapy Catapult began an open-label, U.K. Phase I/II trial to evaluate 2 dose levels of WT1 TCR-transduced T cells in up to 18 patients. This year, the company plans to begin a trial in...
07:00 , Jun 19, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Autism Speaks to Google Patient advocacy group BGI and its subsidiary Complete Genomics Inc. Although obtaining genomic sequences proved relatively cheap and easy, making sense of the sequences proved technically challenging because of the vast...
07:00 , May 22, 2014 |  BC Innovations  |  Translation in Brief

Translational tidbits

Berg's big data dive Berg Pharma LLC is seeking to validate its Interrogative Biology toolkit by striking academic partnerships with the University of Miami Miller School of Medicine and Medical University of South Carolina ....
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Cell Therapy Catapult, Great Ormond Street Hospital, Royal Free Hospital, UCL deal

The partners will develop a tissue repair product for babies with esophageal atresia, a congenital defect in which part of the esophagus does not develop. The partners will develop the product using stem cells from...